CANTOS (Completed)
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP
- Medicine
- canakinumab
- Population
- ASCVD
- Phase
- III
- Starting year
- 2011
- More information
- ClinicalTrials.gov